<DOC>
	<DOCNO>NCT01400464</DOCNO>
	<brief_summary>The factor underlie large interindividual variability response glucocorticoid Giant Cell Arteritis poorly understood . The investigator hypothesize part variability relate pharmacokinetic factor determine genetic polymorphism : hepatic clearance involve cytochrome P450 subfamily 3A ( CYP3A ) drug efflux leukocyte condition P-glycoprotein involved multidrug resistance drug ( ABCB1 ) . The investigator design multicentric prospective pharmacokinetical pharmacogenetic cohort study ass link prednisolone clearance relapse risk giant cell arteritis .</brief_summary>
	<brief_title>Steroids Pharmacokinetics Response Prednisone Therapy Giant Cell Arteritis</brief_title>
	<detailed_description />
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Diagnosis GCA , meet least 3 follow 5 American College Rheumatology ( ACR ) criteria diagnosis GCA : 1 . At least 50 year age disease onset 2 . New onset new type localize pain head 3 . Temporal artery abnormality ( i.e. , temporal artery tenderness palpation decrease pulsation unrelated arteriosclerosis cervical artery ) 4 . ESR great 40 mm first hour Westergren method 5 . Temporal artery biopsy show vasculitis characterize predominance mononuclear cell infiltration granulomatous inflammation , usually multinucleated giant cell Corticoid treatment since less 14 day Signed informed consent Affiliation social security system Dementia Predictable non observance Neoplasia since less 5 year</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Giant Cell Arteritis</keyword>
	<keyword>prednisone</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>